Bayer
Big PharmaBayer is a major pharmaceutical company focused on Oncology, Cardiovascular, Respiratory. Key products include VITRAKVI.
FDA Novel Drug Designations
(2017-2025)See 7 novel approvals →
Bayer at a Glance
- Strong track record with 84% execution quality across 748 trials
- Leading 21 drug targets across portfolio
Bayer's Key Drugs
Bayer's core commercial portfolio centers on GADAVIST, VITRAKVI, KERENDIA, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Disrupted Blood Brain Barrier
Solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation
Chronic Kidney Disease
Metastatic colorectal cancer
Castration-Resistant Prostate Cancer
Bayer's Recent FDA Approvals
Bayer secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Bayer's Therapeutic Areas
Bayer's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 2 biologic and 42 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Bayer's Top Competitors
Bayer's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Bayer Pipeline Snapshot
Bayer has 323 active clinical programs from ClinicalTrials.gov — 71 Phase 3, 84 Phase 2 and 168 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 165/195 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (17)
Discontinued (1)
Company Info
- First Approval
- 1949-09-15
- Latest
- 2026-09-09
- Applications
- 137
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges